<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Penicillamine" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Penicillamine</book-part-id>
      <title-group>
        <title>Penicillamine</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Penbutolol" document-type="chapter">Penbutolol</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="PenicilllinGandV" document-type="chapter">Penicillin G and V</related-object>
    </book-part-meta>
    <body>
      <sec id="Penicillamine.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Penicillamine.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Penicillamine is chelating agent used to decrease copper stores in Wilson disease, which also has immunomodulatory activity in rheumatic diseases such as rheumatoid arthritis, scleroderma and systemic lupus erythematosus. Penicillamine is capable of causing hypersensitivity reactions, some of which are accompanied by liver injury which is typically cholestatic.</p>
        </sec>
        <sec id="Penicillamine.Background">
          <title>Background</title>
          <p>Penicillamine (pen" i sil' a meen) is d-isomer of dimethylcysteine, a breakdown product of penicillin, which was originally isolated from the urine of patients with liver disease receiving penicillin. It was later found to have chelating properties against copper and used in Wilson disease. Penicillamine was also found to lower levels of immune complexes, which led to its use in several rheumatic and immune disorders such as rheumatoid arthritis, scleroderma, systemic lupus erythematosus and primary biliary cirrhosis. Penicillamine was approved for use in Wilson disease in 1960 and is still widely used for that rare indication. The use of penicillamine for rheumatic disorders has decreased markedly with the availability of more modern, potent and less toxic agents. Penicillamine is available in generic forms and under the brand names of Cuprimine and Depen in capsules of 125 and 250 mg and tablets of 250 mg. The usual dose in 250 mg four times daily, increasing based upon effect and tolerance to a maximum of 2 grams daily. Lower doses were used in rheumatic diseases. Common side effects include gastrointestinal upset, metallic taste, bone marrow suppression, rash, pruritus, induction of autoimmune diseases and drug fever. Severe adverse events include aplastic anemia, agranulocytosis, thrombocytopenia, renal dysfunction, proteinuria, Goodpasture syndrome, myasthenia gravis, pemphigus and acute hypersensitivity reactions.</p>
        </sec>
        <sec id="Penicillamine.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Penicillamine has been linked to a characteristic pattern of liver injury arising 1 to 6 weeks after starting therapy, with a distinctly cholestatic pattern of serum enzyme elevations (Case 1). The jaundice due to penicillamine can be severe and prolonged and result in protracted, symptomatic cholestasis, but most cases are self-limited. Immunoallergic manifestations of rash, fever and eosinophilia are common, but not invariable. Interesting, most cases of acute liver injury attributed to penicillamine were reported in patients with rheumatic diseases, only rare instances being reported in Wilson disease.</p>
          <p>Other toxicities of penicillamine therapy such as bone marrow suppression, neutropenia and severe dermatologic features can accompany the hepatic injury. Furthermore, in instances with severe nonhepatic penicillamine toxicities, some degree of hepatic involvement such as mild-to-moderate serum enzyme elevations may occur. Long term toxicities of penicillamine include induction of autoimmune conditions (glomerulonephritis, pneumonitis, lupus-like syndrome) that may be accompanied by autoantibody formation, but autoimmune hepatitis-like syndromes have not been reported.</p>
          <p>Likelihood score: A (well established cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Penicillamine.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The liver injury caused by penicillamine appears to be due to hypersensitivity as shown by its brief latency and the frequency of immunoallergic symptoms and signs. Susceptibility to penicillamine hypersensitivity has been linked to HLA DR3, sulphoxidation status and previous gold allergy, but these factors have not been specifically linked to hepatotoxicity from penicillamine.</p>
        </sec>
        <sec id="Penicillamine.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The hepatotoxicity of penicillamine is typically self-limited, although recovery may be delayed. However, there have been several instances of progressive cholestasis resulting in death or need for liver transplantation arising after acute, severe cholestatic liver injury due to penicillamine. While the pathology of these cases has stressed the chronic cholestatic features and progressive fibrosis, there is little information on bile duct injury and loss. Nevertheless, these instances probably represent vanishing bile duct syndrome. Monitoring of routine liver tests is recommended before and every 6 months during therapy with penicillamine. While ursodiol and corticosteroids are often used in patients with prolonged cholestasis after hepatotoxicity from penicillamine (and other drugs), there is little evidence that they are beneficial. There may be cross reactivity between penicillamine hypersensitivity and allergic responses to penicillin, but this is not invariable. Nevertheless, caution should be employed in use of penicillins in patients with severe penicillamine hypersensitivity.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntirheumaticAgents" document-type="chapter">Antirheumatic Agents</related-object>; <related-object link-type="booklink" source-id="livertox" document-id="ChelatingAgents" document-type="chapter">Chelating Agents</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="WilsonDiseaseAgents" document-type="chapter">Wilson Disease Agents</related-object></p>
          <p>Other Drugs in the Subclass, Wilson Disease: <related-object link-type="booklink" source-id="livertox" document-id="Dimercaprol" document-type="chapter">Dimercaprol</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Trientine" document-type="chapter">Trientine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Zinc" document-type="chapter">Zinc</related-object></p>
        </sec>
      </sec>
      <sec id="Penicillamine.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Penicillamine.Case_1_Immunoallergic_hepa">
          <title>Case 1. Immunoallergic hepatitis due to penicillamine.(<xref ref-type="bibr" rid="Penicillamine.REF.1">1</xref>)</title>
          <p>A 58 year old woman with scleroderma accompanied by arthritis, Raynaud&#x02019;s phenomenon, skin tightening over the face and hands, and lung involvement was placed on penicillamine in a dose of 1.8 g daily. Three weeks later she developed fever and generalized maculopapular rash, followed two days later by dark urine and jaundice. All medications were stopped. She had no previous history of liver disease or drug allergies and did not drink alcohol. Over-the-counter medications included vitamins only. Laboratory testing showed serum bilirubin of 7.4 mg/dL, mild ALT elevations (90 U/L), and marked increases in alkaline phosphatase levels (Table). She had mild eosinophilia (5%) and leukocytosis. Over the next few days, fever and rash resolved and 3 weeks after onset, laboratory tests had returned to normal or near normal.</p>
          <sec id="Penicillamine.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Penicillamine.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Penicillamine.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Penicillamine.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Penicillamine (1.8 g daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Penicillamine.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Penicillamine.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Cholestatic (R=0.3)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Penicillamine.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Penicillamine.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">2+ (jaundice, not hospitalized)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Penicillamine.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Penicillamine.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">3 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Penicillamine.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Penicillamine.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">3 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Penicillamine.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Penicillamine.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Vitamin B6</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Penicillamine.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Penicillamine.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(BEU/L)</th>
                    <th id="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">19</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1.1</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">&#x0003c;1.0</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">14 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3 hd_h_Penicillamine.Td_1_1_1_4 hd_h_Penicillamine.Td_1_1_1_5 hd_h_Penicillamine.Td_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Worsening fever over 4 days followed by rash and jaundice</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">24 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">90</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">33.4</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">7.4</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">5% eosinophils</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">26 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">43</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">32.4</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">5.8</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">33 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">9 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">21</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">14.5</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.6</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">39 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">15 days</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">9</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">7.8</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.9</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_1 hd_h_Penicillamine.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">&#x0003c;30</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">&#x0003c;4.5</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">&#x0003c;1.2</td>
                    <td headers="hd_h_Penicillamine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Penicillamine.Comment">
            <title>Comment</title>
            <p>An early report without viral serology to exclude acute viral hepatitis or modern imaging to exclude biliary obstruction, but the progression of symptoms and laboratory test abnormalities were very typical of drug induced hypersensitivity and liver injury. The latency to onset of symptoms of fever, rash and malaise was 2 to 3 weeks, with jaundice appearing soon thereafter. Immunoallergic symptoms and signs were present and the pattern of serum enzyme elevations was distinctly cholestatic, features that are typical of penicillamine induced liver injury. The features of hypersensitivity usually resolve within a week of stopping therapy, whereas the cholestasis and jaundice are slower to improve. Corticosteroids appear to improve the immunoallergic symptoms and signs promptly, but their effect on the liver injury is less clear.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Penicillamine.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Penicillamine &#x02013; Generic, Cuprimine&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antirheumatic Agents</p>
        <p>Chelating Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Penicillamine">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Penicillamine.CHEMICAL_FORMULA_AND_STRUC">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Penicillamine.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <th id="hd_b_Penicillamine.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_b_Penicillamine.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_b_Penicillamine.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_b_Penicillamine.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
              <tr>
                <td headers="hd_b_Penicillamine.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Penicillamine</td>
                <td headers="hd_b_Penicillamine.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134970687">52-67-5</ext-link>
                </td>
                <td headers="hd_b_Penicillamine.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C5-H11-N-O2-S</td>
                <td headers="hd_b_Penicillamine.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134970687" document-id-type="sid" document-type="summary" object-id="134970687" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Penicillamine.CITED_REFERENCE">
        <title>CITED REFERENCE</title>
        <ref-list id="Penicillamine.CITED_REFERENCE.reflist0">
          <ref id="Penicillamine.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Rau</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Weber</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>B&#x000f6;ni</surname>
                  <given-names>A.</given-names>
                </name>
              </person-group>
              <comment>[Allergic-toxic liver damage due to D-penicillamine]</comment>
              <source>Schweiz Med Wochenschr</source>
              <year>1972</year>
              <volume>102</volume>
              <fpage>1226</fpage>
              <lpage>8</lpage>
              <comment>German.</comment>
              <pub-id pub-id-type="pmid">5055042</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Penicillamine.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 25 July 2020</p>
        <ref-list id="Penicillamine.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Penicillamine.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Drugs used in rheumatic diseases: penicillamine. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 542.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; mentions that there have been 18 published cases of jaundice due to penicillamine, almost all cholestatic with latency of 2-4 weeks and features of hypersensitivity).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Penicillamine.REF.byrns.2018">
            <mixed-citation publication-type="book">Byrns MC, Penning TM. Treatment of metal exposure. Environmental toxicology: carcinogens and heavy metals. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1311-5.</mixed-citation>
          </ref>
          <ref id="Penicillamine.REF.walshe.1956.487">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Walshe</surname>
                  <given-names>JM</given-names>
                </name>
              </person-group>
              <article-title>Penicillamine, a new oral therapy for Wilson's disease.</article-title>
              <source>Am J Med</source>
              <year>1956</year>
              <volume>21</volume>
              <fpage>487</fpage>
              <lpage>95</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Initial studies on efficacy of oral penicillamine [&#x003b2;,&#x003b2;-dimethyl cysteine, a monothiol] in inducing cupruresis in Wilson disease and lack of effect of cysteine and methionine; no toxic reactions were observed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">13362281</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.walshe.1968.6">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Walshe</surname>
                  <given-names>JM</given-names>
                </name>
              </person-group>
              <article-title>Toxic reactions to penicillamine in patients with Wilson&#x02019;s disease.</article-title>
              <source>Postgrad Med J</source>
              <year>1968</year>
              <supplement>Suppl</supplement>
              <fpage>6</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Summary of side effects of penicillamine representing 126 patient years of use in Wilson disease; important toxicities included nephrotic syndrome, lupus-like syndrome, thrombocytopenia, urticaria and one case of a 9 year old with urticaria, fever, malaise and jaundice, with positive rechallenge and inability to tolerate the drug and resultant death from Wilson disease).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4867248</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.sternlieb.1968.352">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sternlieb</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Scheinberg</surname>
                  <given-names>IH</given-names>
                </name>
              </person-group>
              <article-title>Prevention of Wilson's disease in asymptomatic patients.</article-title>
              <source>N Engl J Med</source>
              <year>1968</year>
              <volume>278</volume>
              <fpage>352</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 42 asymptomatic persons who were diagnosed with Wilson disease and treated with penicillamine for up to 8 years, none developed symptomatic disease).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5635646</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.rau.1972.1226">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Rau</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Weber</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>B&#x000f6;ni</surname>
                  <given-names>A.</given-names>
                </name>
              </person-group>
              <comment>[Allergic-toxic liver damage due to D-penicillamine]</comment>
              <source>Schweiz Med Wochenschr</source>
              <year>1972</year>
              <volume>102</volume>
              <fpage>1226</fpage>
              <lpage>8</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(58 year old with scleroderma developed fever, rash and jaundice 2-3 weeks after starting penicillamine with bilirubin 7.4 mg/dL, ALT 90 U/L, Alk P 8 times ULN, with resolution within 2 weeks of stopping: see Case 1).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5055042</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.walshe.1973.441">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Walshe</surname>
                  <given-names>JM</given-names>
                </name>
              </person-group>
              <article-title>Copper chelation in patients with Wilson&#x02019;s disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.</article-title>
              <source>Q J Med</source>
              <year>1973</year>
              <volume>42</volume>
              <fpage>441</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Trientine induced a cupruresis in 18 patients with Wilson disease, which was less than with penicillamine, but was substantial particularly in patients who had never been treated, suggesting that it might be an alternative for patients intolerant to penicillamine therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4728043</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.siegmund.1976.172">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Siegmund</surname>
                  <given-names>H.</given-names>
                </name>
              </person-group>
              <comment>[Intrahepatic cholestasis following treatment with D-penicillamine and indomethacin]</comment>
              <source>Med Welt</source>
              <year>1976</year>
              <volume>27</volume>
              <issue>4</issue>
              <fpage>172</fpage>
              <lpage>3</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(38 year old woman with rheumatoid arthritis developed jaundice 5 weeks after starting penicillamine and indomethacin [bilirubin 5.5 mg/dL, ALT 120 U/L, Alk P 10 times ULN], jaundice resolving within 4 weeks of stopping both drugs, but Alk P remained high).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">1250131</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.sacher.1977.481">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sacher</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Thaler</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Toxic hepatitis after therapeutic doses of benorylate and D-penicillamine.</article-title>
              <source>Lancet</source>
              <year>1977</year>
              <volume>1</volume>
              <fpage>481</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(13 year old girl with rheumatoid arthritis developed jaundice 5 months after starting penicillamine with recovery in 3 months; no specifics given; benorylate is an ester of acetylsalicylic acid and acetaminophen).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">65582</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.barzilai.1978.98">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Barzilai</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Dickstein</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Enat</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Bassan</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Lichtig</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Gellei</surname>
                  <given-names>B.</given-names>
                </name>
              </person-group>
              <article-title>Case report: cholestatic jaundice caused by D-penicillamine.</article-title>
              <source>Ann Rheum Dis</source>
              <year>1978</year>
              <volume>37</volume>
              <fpage>98</fpage>
              <lpage>100</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(56 year old man with rheumatoid arthritis developed jaundice and pruritus 4 weeks after starting penicillamine [bilirubin 15 mg/dL, ALT 203 U/L, Alk P 3 times ULN]; underwent laparotomy, with subsequent rise in bilirubin to 88 mg/dL, renal failure and death).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">629612</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.mcleod.1979.965">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>McLeod</surname>
                  <given-names>BD</given-names>
                </name>
                <name name-style="western">
                  <surname>Kinsella</surname>
                  <given-names>TD</given-names>
                </name>
              </person-group>
              <article-title>Cholestasis associated with D-penicillamine for rheumatoid arthritis.</article-title>
              <source>Can Med Assoc J</source>
              <year>1979</year>
              <volume>120</volume>
              <fpage>965</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(41 year old woman with rheumatoid arthritis developed jaundice 3 weeks after starting penicillamine [bilirubin 3.3 mg/dL, AST 117 U/L, Alk P 1132 U/L], jaundice resolving within 2 weeks and enzyme elevations within 11 weeks of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">436073</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.crickx.1979.212">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Crickx</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Leger</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Auquier</surname>
                  <given-names>L</given-names>
                </name>
              </person-group>
              <comment>[Granulomatous hepatitis and parotiditis induced by d-penicillamine in a case of rheumatoid arthritis]</comment>
              <source>Nouv Presse Med</source>
              <year>1979</year>
              <volume>8</volume>
              <fpage>212</fpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(50 year old woman with rheumatoid arthritis developed cholestatic jaundice and parotiditis soon after starting penicillamine, liver and parotid biopsies demonstrating granulomas; no specifics given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">554085</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.jaffe.1979.58">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jaffe</surname>
                  <given-names>IA</given-names>
                </name>
              </person-group>
              <article-title>Penicillamine in rheumatoid arthritis: clinical pharmacology and biochemical properties.</article-title>
              <source>Scand J Rheumatol Suppl</source>
              <year>1979</year>
              <issue>28</issue>
              <fpage>58</fpage>
              <lpage>64</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Reports that penicillamine leads to improvements in stiffness and pain in rheumatoid arthritis after 8-12 weeks of therapy and can induce a variety of autoimmune conditions including pemphigus, myasthenia, glomerulonephritis, polymyositis, hemolytic anemia, lupus, Sj&#x000f6;gren's syndrome and thrombocytopenic purpura).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">287192</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.baum.1979.65">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Baum</surname>
                  <given-names>J.</given-names>
                </name>
              </person-group>
              <article-title>The use of penicillamine in the treatment of rheumatoid arthritis and scleroderma.</article-title>
              <source>Scand J Rheumatol Suppl</source>
              <year>1979</year>
              <issue>28</issue>
              <fpage>65</fpage>
              <lpage>70</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In review of literature on 1190 patients treated with penicillamine for 4-12 months, beneficial response rates averaged 62%, but significant side effects found in 37% of patients).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">377472</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.hill.1979.94">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hill</surname>
                  <given-names>HFH</given-names>
                </name>
              </person-group>
              <article-title>Penicillamine in rheumatoid arthritis: adverse effects.</article-title>
              <source>Scand J Rheumatol Suppl</source>
              <year>1979</year>
              <issue>28</issue>
              <fpage>94</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of skin adverse events and fatalities due to penicillamine, deaths largely due to bone marrow toxicity; no mention of hepatotoxicity or cholestasis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">156393</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.wollheim.1979.100">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wollheim</surname>
                  <given-names>FA</given-names>
                </name>
                <name name-style="western">
                  <surname>Lindstr&#x000f6;m</surname>
                  <given-names>CG</given-names>
                </name>
              </person-group>
              <article-title>Liver abnormalities in penicillamine treated rheumatoid arthritis.</article-title>
              <source>Scand J Rheumatol Suppl</source>
              <year>1979</year>
              <issue>28</issue>
              <fpage>100</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 99 patients followed prospectively during penicillamine therapy, 6 developed serum enzyme abnormalities without jaundice, reversible within weeks of stopping in all, not always recurring with restarting penicillamine at lower doses).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">287188</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.rosenbaum.1980.152">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Rosenbaum</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Katz</surname>
                  <given-names>WA</given-names>
                </name>
                <name name-style="western">
                  <surname>Schumacher</surname>
                  <given-names>HR</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.</article-title>
              <source>Ann Rheum Dis</source>
              <year>1980</year>
              <volume>39</volume>
              <fpage>152</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two patients with rheumatoid arthritis with penicillamine hepatotoxicity; 43 year old woman developed enzyme elevations [normal bilirubin, AST 440 U/L, Alk P ~2 times ULN] without symptoms 2 months after starting penicillamine, resolving rapidly on stopping and recurring with rechallenge; 60 year old man developed jaundice 2 weeks after starting penicillamine [bilirubin 2.2 mg/dL, AST 128 U/L, Alk P 8 times ULN], resolving slowly over next 9 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7387219</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.seibold.1981.554">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Seibold</surname>
                  <given-names>JR</given-names>
                </name>
                <name name-style="western">
                  <surname>Lynch</surname>
                  <given-names>CJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Medsger</surname>
                  <given-names>TA</given-names>
                </name>
              </person-group>
              <article-title>Cholestasis associated with D-penicillamine therapy: case report and review of the literature.</article-title>
              <source>Arthritis Rheum</source>
              <year>1981</year>
              <volume>24</volume>
              <fpage>554</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(26 year old woman with lupus developed fever and rash after 10 days of penicillamine which improved on stopping, but recurred after a single tablet of penicillamine with fever, rash, arthritis followed by jaundice [bilirubin 7.9 mg/dL, ALT 315 U/L, Alk P 358 U/L], resolving within 7 weeks).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7213433</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.jensen.1981.3471">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jensen</surname>
                  <given-names>OH</given-names>
                </name>
              </person-group>
              <comment>[Penicillamine induced liver involvement]</comment>
              <source>Ugeskr Laeger</source>
              <year>1981</year>
              <volume>143</volume>
              <fpage>3471</fpage>
              <lpage>2</lpage>
              <comment>Danish.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(64 year old man with rheumatoid arthritis developed jaundice after a year of penicillamine therapy and had sudden worsening when it was inadvertently restarted with fever and jaundice [bilirubin ~3.0 mg/dL, Alk P and AST 3 times ULN], symptoms resolving rapidly on stopping and liver tests returning to normal within 3 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7336507</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.multz.1981.674">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Multz</surname>
                  <given-names>CV</given-names>
                </name>
              </person-group>
              <article-title>Cholestatic hepatitis caused by penicillamine.</article-title>
              <source>JAMA</source>
              <year>1981</year>
              <volume>246</volume>
              <fpage>674</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(53 year old woman with rheumatoid arthritis developed jaundice 4 weeks after starting penicillamine [bilirubin 6.4 mg/dL, AST 390 U/L, Alk P 820 U/L], jaundice resolving in 2 weeks; remission in arthritis during period of jaundice).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7253120</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.jobdeslandre.1982.2356">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Job-Deslandre</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Delrieu</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Rondier</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Guedri</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Delbarre</surname>
                  <given-names>F</given-names>
                </name>
              </person-group>
              <article-title>Hepatitie cholestatique et anticorps anti-DNA induits par la d-penicillamine.</article-title>
              <source>Nouv Presse Med</source>
              <year>1982</year>
              <volume>11</volume>
              <fpage>2356</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(33 year old with rheumatoid arthritis treated with penicillamine for 4 years developed jaundice and lupus-like syndrome [bilirubin not given, ALT 61 U/L, Alk P 3.6 times ULN, ANA 1:500], liver abnormalities resolving within 2 months, but ANA remaining positive).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6981100</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.grauer.1983.1997">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Grauer</surname>
                  <given-names>JL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fonteille</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zarski</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Gintz</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Phelip</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Cabanel</surname>
                  <given-names>G</given-names>
                </name>
              </person-group>
              <comment>[Erythema nodosum and cholestatic hepatitis during treatment with D-penicillamine]</comment>
              <source>Presse Med</source>
              <year>1983</year>
              <volume>12</volume>
              <fpage>1997</fpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(62 year old with rheumatoid arthritis developed fever 20 days after starting penicillamine, resolving on stopping and reappearing 2 months after restarting along with rash, but no jaundice [bilirubin not given, AST 1.5 times, Alk P 4.5 times ULN], resolving within 2 weeks of stopping again).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6225106</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.emery.1984.626">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Emery</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Panayi</surname>
                  <given-names>GS</given-names>
                </name>
                <name name-style="western">
                  <surname>Huston</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Welsh</surname>
                  <given-names>KI</given-names>
                </name>
                <name name-style="western">
                  <surname>Mitchell</surname>
                  <given-names>SC</given-names>
                </name>
                <name name-style="western">
                  <surname>Shah</surname>
                  <given-names>RR</given-names>
                </name>
                <name name-style="western">
                  <surname>Idle</surname>
                  <given-names>JR</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>D-penicillamine induced toxicity in rheumatoid arthritis : the role of sulphoxidation status and HLA-DR3.</article-title>
              <source>J Rheumatol</source>
              <year>1984</year>
              <volume>11</volume>
              <fpage>626</fpage>
              <lpage>32</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 66 patients with rheumatoid arthritis treated with penicillamine, adverse events [largely renal, bone marrow and skin toxicities] were more common in those with low sulphoxidation indices [60%] than in those with normal values [17%], and with HLA DR3 [60% vs 29%], without interaction of the two predictive factors).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6334741</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.gefel.1985.303">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gefel</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Hrats</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Lijovetsky</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Eliakim</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Cholestatic jaundice associated with d-penicillamine therapy.</article-title>
              <source>Scand J Rheumatol</source>
              <year>1985</year>
              <volume>14</volume>
              <fpage>303</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(35 year old man with cystinuria developed fever and rash 16 days after starting penicillamine followed by jaundice [peak bilirubin 14.9 mg/dL, ALT 149 U/L, Alk P 553 U/L], biopsy showing intrahepatic cholestasis; prednisone was started when bilirubin worsened; jaundice resolved within 3 months and abnormal Alk P within 9 months of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4048879</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.devogelaer.1985.35">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Devogelaer</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Huaux</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Coche</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Rahier</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Nagant de Deuxchaisnes</surname>
                  <given-names>C</given-names>
                </name>
              </person-group>
              <article-title>A case of cholestatic hepatitis associated with D-penicillamine therapy for rheumatoid arthritis.</article-title>
              <source>Int J Clin Pharmacol Res</source>
              <year>1985</year>
              <volume>5</volume>
              <fpage>35</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(72 year old man with rheumatoid arthritis developed pruritus and jaundice 1 month after starting penicillamine [bilirubin 16.2 mg/dL, ALT 227 U/L, Alk P 290 U/L], jaundice resolving within 3 weeks and serum enzymes within 6 weeks of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3997313</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.abadia.1985.590">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Abadia</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Jammet</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Christoforov</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Cremer</surname>
                  <given-names>GA</given-names>
                </name>
              </person-group>
              <comment>[Hepatotoxicity of drugs commonly used in rheumatology]</comment>
              <source>Ann Med Interne (Paris)</source>
              <year>1985</year>
              <volume>136</volume>
              <fpage>590</fpage>
              <lpage>600</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of hepatotoxicity of rheumatologic agents; mentions 16 cases of penicillamine induced liver injury, typically with immunoallergic features and cholestatic pattern with resolution in 2-4 weeks, recurrence after reexposure in 5 instances; one fatality).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2868682</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.kumar.1985.337">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Bhat</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Gupta</surname>
                  <given-names>DK</given-names>
                </name>
                <name name-style="western">
                  <surname>Goel</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Malaviya</surname>
                  <given-names>AN</given-names>
                </name>
              </person-group>
              <article-title>D-penicillamine-induced acute hypersensitivity pneumonitis and cholestatic hepatitis in a patient with rheumatoid arthritis.</article-title>
              <source>Clin Exp Rheumatol</source>
              <year>1985</year>
              <volume>3</volume>
              <fpage>337</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(45 year old woman with rheumatoid arthritis developed rash, fever and hypersensitivity pneumonitis 10 days after starting penicillamine, responding to prednisone therapy but with subsequent jaundice [peak bilirubin 30 mg/dL, ALT 300 U/L, Alk P 5 times ULN], resolving within 4 weeks of stopping; recurrence of dyspnea and jaundice after unintentional rechallenge).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4085166</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.choudhuri.1986.299">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Choudhuri</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Tandon</surname>
                  <given-names>RK</given-names>
                </name>
              </person-group>
              <article-title>D-penicillamine induced cholestatic jaundice.</article-title>
              <source>J Assoc Physicians India</source>
              <year>1986</year>
              <volume>34</volume>
              <fpage>299</fpage>
              <lpage>300</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(45 year old woman with rheumatoid arthritis developed rash, fever and dyspnea within 2 weeks of starting penicillamine [initial bilirubin 7.0 mg/dL, ALT 200 U/L, Alk P 5 times ULN]; allergic alveolitis responding rapidly to prednisone, but bilirubin rising to 30 mg/dL; positive rechallenge; appears to be same patient as described by Kumar [1985]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3759835</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.roux.1986.21">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Roux</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonnefoy-Cudraz</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Antipoff</surname>
                  <given-names>GM</given-names>
                </name>
              </person-group>
              <comment>[Liver complications caused by D-penicillamine. Apropos of a case]</comment>
              <source>Rev Rhum Mal Osteoartic</source>
              <year>1986</year>
              <volume>53</volume>
              <fpage>21</fpage>
              <lpage>3</lpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(60 year old woman with rheumatoid arthritis developed rash and pruritus followed by jaundice 6 weeks after starting penicillamine [bilirubin 8.2 mg/dL, ALT 61 U/L, Alk P 2158 U/L, 14% eosinophilia], resolving slowly upon stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3704507</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.scheinberg.1987.209">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Scheinberg</surname>
                  <given-names>IH</given-names>
                </name>
                <name name-style="western">
                  <surname>Jaffe</surname>
                  <given-names>ME</given-names>
                </name>
                <name name-style="western">
                  <surname>Sternlieb</surname>
                  <given-names>I</given-names>
                </name>
              </person-group>
              <article-title>The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.</article-title>
              <source>N Engl J Med</source>
              <year>1987</year>
              <volume>317</volume>
              <fpage>209</fpage>
              <lpage>13</lpage>
              <pub-id pub-id-type="pmid">3600712</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.cooperative_systemic_studies_of_rheumatic_disease_group.1987.67">
            <element-citation publication-type="journal">
              <person-group>
                <collab>Cooperative Systemic Studies of Rheumatic Disease Group</collab>
              </person-group>
              <article-title>Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis.</article-title>
              <source>J Rheumatol</source>
              <year>1987</year>
              <volume>14</volume>
              <fpage>67</fpage>
              <lpage>73</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 148 patients with rheumatoid arthritis continued on long term penicillamine, side effects included rash, gastrointestinal upset, proteinuria, bone marrow suppression, myasthenia, myositis, drug fever and pemphigus; no late hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2952797</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.moens.1987.1115">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Moens</surname>
                  <given-names>HJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Ament</surname>
                  <given-names>BJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Feltkamp</surname>
                  <given-names>BW</given-names>
                </name>
                <name name-style="western">
                  <surname>van der Korst</surname>
                  <given-names>JK</given-names>
                </name>
              </person-group>
              <article-title>Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.</article-title>
              <source>J Rheumatol</source>
              <year>1987</year>
              <volume>14</volume>
              <fpage>1115</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(HLA testing done on 86 patients with rheumatoid arthritis started on penicillamine including 22 on long term [5-7 years] therapy; HLA-DR4 was associated with thrombocytopenia [94% vs 67%] and HLA-B8/DR3 with proteinuria [60% vs 9%], but no association with effectiveness; no cases of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3437418</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.berbis.1987.377">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Berbis</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Fabre</surname>
                  <given-names>JF</given-names>
                </name>
                <name name-style="western">
                  <surname>Privat</surname>
                  <given-names>Y</given-names>
                </name>
              </person-group>
              <comment>[Cholestatic hepatitis: a rare complication of the treatment with D. penicillamine]</comment>
              <source>Ann Dermatol Venereol</source>
              <year>1987</year>
              <volume>114</volume>
              <fpage>377</fpage>
              <lpage>9</lpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(22 year old woman with scleroderma developed fever, rash, and weakness followed by jaundice 10 days after starting penicillamine [bilirubin 1.5 mg/dL, ALT 381 U/L, Alk P 409 U/L with mild eosinophilia], resolving within 3 weeks of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3605968</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.guerrero_navarro.1988.221">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Guerrero Navarro</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Molina Lorente</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Mur Villacampa</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Revillo Pinilla</surname>
                  <given-names>P.</given-names>
                </name>
              </person-group>
              <comment>[Cholestatic hepatitis caused by D-penicillamine]</comment>
              <source>Rev Esp Enferm Apar Dig</source>
              <year>1988</year>
              <volume>73</volume>
              <fpage>221</fpage>
              <comment>Spanish.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(61 year old man developed fever, rash, pruritus and jaundice 3 days after starting penicillamine [peak bilirubin 10.6 mg/dL, ALT 198 U/L, Alk P 336 U/L], resolving within 2 weeks).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3375535</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.fishel.1989.609">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fishel</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Tishler</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Caspi</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Yaron</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Fatal aplastic anaemia and liver toxicity caused by d-penicillamine treatment of rheumatoid arthritis.</article-title>
              <source>Ann Rheum Dis</source>
              <year>1989</year>
              <volume>48</volume>
              <fpage>609</fpage>
              <lpage>10</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(65 year old woman with rheumatoid arthritis developed thrombocytopenia 3 months after starting penicillamine [platelet count 10,000/&#x000b5;L, white cell count 3000/&#x000b5;L, hemoglobin 6.7 gm/dL] and subsequently developed jaundice [bilirubin 10.0 mg/dL, AST 80 U/L, Alk P 120 U/L], dying 17 days later with bone marrow, renal and hepatic failure).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2774703</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.jacobs.1994.770">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jacobs</surname>
                  <given-names>JW</given-names>
                </name>
                <name name-style="western">
                  <surname>Van der Weide</surname>
                  <given-names>FR</given-names>
                </name>
                <name name-style="western">
                  <surname>Kruijsen</surname>
                  <given-names>MW</given-names>
                </name>
              </person-group>
              <article-title>Fatal cholestatic hepatitis caused by D-penicillamine.</article-title>
              <source>Br J Rheumatol</source>
              <year>1994</year>
              <volume>33</volume>
              <fpage>770</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(37 year old woman with rheumatoid arthritis developed fever, granulocytopenia and jaundice 10 days after starting penicillamine [without rash or eosinophilia], with intrahepatic cholestasis on liver biopsy and subsequent persistent jaundice and cholestasis and death from sepsis 14 months later).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8055207</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.barthel.1995.1253">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Barthel</surname>
                  <given-names>HR</given-names>
                </name>
                <name name-style="western">
                  <surname>Hiepe</surname>
                  <given-names>F</given-names>
                </name>
              </person-group>
              <comment>[Lupus erythematosus and liver diseases]</comment>
              <source>Dtsch Med Wochenschr</source>
              <year>1995</year>
              <volume>120</volume>
              <fpage>1253</fpage>
              <lpage>7</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of liver abnormalities in lupus erythematosus; penicillamine can induce a lupus-like syndrome which resolves when the drug is stopped, although ANA positivity may persist).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7671785</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.harders.1977.10">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Harders</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Cohnen</surname>
                  <given-names>E</given-names>
                </name>
              </person-group>
              <article-title>Preparation of and clinical experiences with trien for the treatment of Wilson&#x02019;s disease in absolute intolerance of D-penicillamine.</article-title>
              <source>Proc R Soc Med</source>
              <year>1977</year>
              <volume>70</volume>
              <supplement>Suppl 3</supplement>
              <fpage>10</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(28 year old woman who was intolerant to penicillamine was successfully treated with trientine prepared by an improved method, with prompt cupruresis and improvement in neurologic symptoms).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">122652</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to penicillamine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.roberts.2008.2089">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Roberts</surname>
                  <given-names>EA</given-names>
                </name>
                <name name-style="western">
                  <surname>Schilsky</surname>
                  <given-names>ML</given-names>
                </name>
              </person-group>
              <article-title>AASLD. Diagnosis and treatment of Wilson disease: an update.</article-title>
              <source>Hepatology</source>
              <year>2008</year>
              <volume>47</volume>
              <fpage>2089</fpage>
              <lpage>111</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Thorough review of the cause, natural history, diagnosis and treatment of Wilson disease with specific recommendations for use of penicillamine, trientine and zinc).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18506894</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.walshe.2009.2289">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Walshe</surname>
                  <given-names>JM</given-names>
                </name>
              </person-group>
              <article-title>The conquest of Wilson's disease.</article-title>
              <source>Brain</source>
              <year>2009</year>
              <volume>132</volume>
              <issue>Pt 8</issue>
              <fpage>2289</fpage>
              <lpage>95</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(History of the initial description of Wilson disease, its link to copper accumulation, and therapies several of which were developed by the author).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19596747</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.weiss.2012.1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Weiss</surname>
                  <given-names>KH</given-names>
                </name>
                <name name-style="western">
                  <surname>Stremmel</surname>
                  <given-names>W</given-names>
                </name>
              </person-group>
              <article-title>Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring.</article-title>
              <source>Curr Gastroenterol Rep</source>
              <year>2012</year>
              <volume>14</volume>
              <issue>1</issue>
              <fpage>1</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the diagnosis and management of Wilson disease, including the role of genetic testing and the choice of medical therapies).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22083169</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.weiss.2013.1028">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Weiss</surname>
                  <given-names>KH</given-names>
                </name>
                <name name-style="western">
                  <surname>Thurik</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Gotthardt</surname>
                  <given-names>DN</given-names>
                </name>
                <name name-style="western">
                  <surname>Sch&#x000e4;fer</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Teufel</surname>
                  <given-names>U</given-names>
                </name>
                <name name-style="western">
                  <surname>Wiegand</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Merle</surname>
                  <given-names>U</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>EUROWILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.</article-title>
              <source>Clin Gastroenterol Hepatol</source>
              <year>2013</year>
              <volume>11</volume>
              <fpage>1028</fpage>
              <lpage>35.e1</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 380 patients with Wilson disease from referral centers in Germany and Austria, including 141 who were treated with trientine and 326 with penicillamine, found similar rates of improvement in liver disease but higher rate of improvement in neurologic features with penicillamine, along with higher rates of adverse events leading to discontinuation [29% vs 7%], although there were no therapy related deaths; reasons for discontinuation in the penicillamine group included arthralgias, gastrointestinal upset, myalgias, leukopenia, rash, lupus erythematosus and increase in ANA titers; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23542331</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which was attributed to penicillamine or other agents used to treat Wilson disease).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, one case was attributed to penicillamine in a woman with scleroderma who developed fatigue, jaundice and rash 3 weeks after starting penicillamine [bilirubin 5.6 rising to 10.5 mg/dL, ALT 308 U/L, Alk P 377 U/L], resolving slowly and with persistent, mild elevations in ALT and Alk P during long term follow up).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.pfeiffenberger.2018.1261">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pfeiffenberger</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Beinhardt</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Gotthardt</surname>
                  <given-names>DN</given-names>
                </name>
                <name name-style="western">
                  <surname>Haag</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Freissmuth</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Reuner</surname>
                  <given-names>U</given-names>
                </name>
                <name name-style="western">
                  <surname>Gauss</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Pregnancy in Wilson's disease: management and outcome.</article-title>
              <source>Hepatology</source>
              <year>2018</year>
              <volume>67</volume>
              <fpage>1261</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 282 pregnancies in 136 patients with Wilson disease analyzed in a retrospective, multicenter study, spontaneous abortion was less common among patients being treated with penicillamine [17%] or zinc [10%] than untreated patients [41%], which was proportionally greater than with trientine [28%] and similar to that in patients who discontinued therapy during pregnancy [36%]; worsening of liver disease arose in some patients on treatment but was self-limiting and resolved after delivery; birth defects were found in 7 of 209 [3%] newborns overall and in 4 of 98 women taking penicillamine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28859232</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.roberts.2018.56">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Roberts</surname>
                  <given-names>EA</given-names>
                </name>
              </person-group>
              <article-title>Update on the diagnosis and management of Wilson disease.</article-title>
              <source>Curr Gastroenterol Rep</source>
              <year>2018</year>
              <volume>20</volume>
              <fpage>56</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of recent advances in the understanding of the pathogenesis, clinical features, diagnosis, and treatment of Wilson disease).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30397835</pub-id>
            </element-citation>
          </ref>
          <ref id="Penicillamine.REF.appenzellerherzog.2019.2136">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Appenzeller-Herzog</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Mathes</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Heeres</surname>
                  <given-names>MLS</given-names>
                </name>
                <name name-style="western">
                  <surname>Weiss</surname>
                  <given-names>KH</given-names>
                </name>
                <name name-style="western">
                  <surname>Houwen</surname>
                  <given-names>RHJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Ewald</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.</article-title>
              <source>Liver Int</source>
              <year>2019</year>
              <volume>39</volume>
              <fpage>2136</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature on therapies of Wilson disease found no differences in outcomes with penicillamine vs zinc, but higher rates of adverse events and discontinuations with penicillamine; no mention of hepatotoxicity or ALT elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31206982</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Penicillamine.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(penicillamine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222010/4/01%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Penicillamine: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=penicillamine">Trials on Penicillamine: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
